Berliner Institut für Gesundheitsforschung - Charité und Max-Delbrück-Centrum

Bladder cancer: When to use chemotherapy?

In bladder cancer, the body's own fight against the tumor by the immune system contributes to the effectiveness of chemotherapy, according to researchers* at Charité and BIH.

To the press release

Tiny molecules with a big impact

Scientists from the BIH and Charité discovered hundreds of previously unknown variations in genes that have a sometimes drastic impact on the concentration of these small molecules in the blood.

To the press release

Safeguarding access to and quality of biosamples in research

BMBF awards German Biobank Node (GBN) € 3.5 million in funding.

To the press release

ACE inhibitors and COVID-19 in hypertensive patients

Scientists from the BIH and Charité have now found that the immune cells of patients with hypertension are already pre-activated, and that this pre-activation is greatly enhanced under COVID-19.

To the press release

The BIH at the Charité: "We belong together!"

On 1 January 2021, BIH will become the translational research division of the Charité, forming its third pillar alongside the Clinical Center and the Medical Faculty.

To the press release

In memory of Prof. Duska Dragun

We deeply mourn the passing of Professor Duska Dragun - founder of the Clinician Scientist Program and Director of the BIH Biomedical Innovation Academy

Our mission: Translation!

The mission of the BIH is medical translation: The BIH aims to translate findings from biomedical research into new approaches for personalised prediction, prevention and therapy and, conversely, to develop new research approaches from clinical observations. The goal is always the medical benefit for patients*.

More about the mission of the BIH

Corona research at full speed

To protect against SARS-CoV-2, the BIH works largely in the home office. Meanwhile, research on Corona/COVID-19 is in full swing.